Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
MD Anderson Study Status
Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Cyclophosphamide, Fludarabine, Fludarabine Phosphate
This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) works in treating patients with ovarian cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed). LN-145 is made by collecting and growing specialized white blood cells (called T-cells) that are collected from the patient's tumor. The T cells may specifically recognize, target, and kill the tumor cells.
Information and next steps
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials: